| Ovarian Clear Cell Adenocarcinoma studied in …STUDIED_INderived62 of 62show fewer |
|---|
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07718854Phase 2 · recruiting Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226507Phase 1 · terminated A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039801Phase 1 · recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02713386Phase 1/Phase 2 · completed Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03648489Phase 2 · completed Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02923739Phase 2 · terminated Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498597Phase 1 · unknown AMT-151 in Patients With Selected Advanced Solid Tumours · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02059265Phase 2 · terminated Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01097746Phase 2 · completed First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924245Phase 1 · terminated Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00888615Phase 2 · completed Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00989651Phase 1 · completed Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02853318Phase 2 · completed Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00108745Phase 3 · unknown Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315430Phase 2 · completed Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00979992Phase 2 · completed Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01504126early Phase 1 · completed Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01074411Phase 1 · completed Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01196429Phase 2 · completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00262847Phase 3 · completed Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00993616Phase 2 · completed Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00079430Phase 1 · completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00085358Phase 1 · completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01459380Phase 1 · completed Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00357448Phase 1 · completed Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01489371Phase 1 · completed EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00939809Phase 2 · completed A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01275664NA · terminated Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01080521completed Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719303Phase 3 · unknown Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00466960Phase 2 · completed Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004221Phase 2 · terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00897442completed Collecting Tumor Samples From Patients With Gynecological Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00059787Phase 2 · completed Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060359Phase 1 · completed Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00814086Phase 1 · completed Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01492920Phase 3 · withdrawn Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01294293Phase 1 · completed TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00002913Phase 1 · completed Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (18 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |